Malek Bou-Diab

Portefeuillebeheerder-Aandelen bij Bellevue Asset Management AG

Finance

Profiel

Dr. Malek Bou-Diab is a Lead Portfolio Manager at Bellevue Asset Management AG.
He joined the firm in 2009.
Dr. Malek was a Portfolio Manager at Julius Baer Asset Management and was a Quant Risk Manager at Deutsche Bank in London.
He holds a Ph.D.
in Theoretical Physics from Zurich's Swiss Federal Institute of Technology (ETH) in Zurich.

Actieve functies van Malek Bou-Diab

Bedrijven	Functie	Begin
Bellevue Asset Management AG Bellevue Asset Management AG Investment ManagersFinance Bellevue Asset Management AG (Bellevue AM) is the wholly-owned asset management subsidiary of Bellevue Group AG (SWX: BBN), an independent Swiss financial group. The firm is headquartered in Küsnacht, Switzerland and has additional offices in Germany, Austria and Luxembourg. Founded in 1993, Bellevue AM provides a diverse spectrum of top-tier investment solutions with a focus on global healthcare sector for private and institutional clients. They offer their flagship investment vehicle, the listed investment company BB Biotech AG.	Portefeuillebeheerder-Aandelen	01-01-2009

Alle actieve functies van Malek Bou-Diab

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Malek Bou-Diab in detail bekijken

Connecties

Eerstegraads connecties

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Bedrijven in privébezit	1
Bellevue Asset Management AG Bellevue Asset Management AG Investment ManagersFinance Bellevue Asset Management AG (Bellevue AM) is the wholly-owned asset management subsidiary of Bellevue Group AG (SWX: BBN), an independent Swiss financial group. The firm is headquartered in Küsnacht, Switzerland and has additional offices in Germany, Austria and Luxembourg. Founded in 1993, Bellevue AM provides a diverse spectrum of top-tier investment solutions with a focus on global healthcare sector for private and institutional clients. They offer their flagship investment vehicle, the listed investment company BB Biotech AG.	Finance